The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization
Open accessAbstract
BACKGROUND: The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has not been delineated. METHODS: In this double-blind, randomized trial, in a primary analysis involving 7243 patients under the age of 75 years receiving aspirin, we evaluated up to 30 months of treatment with prasugrel (10 mg daily) versus clopidogrel (75 mg daily). In a secondary analysis involving 2083 patients 75 years of age or older, we evaluated 5 mg of prasugrel versus 75 mg of clopidogrel. RESULTS: At a median follow-up of 17 months, the primary end point of death from cardiovascular causes, myocardial infarction, or stroke among patients under the age of 75 years occurred in 13.9% of the prasugrel group and 16.0% of the clopidogrel group (hazard ratio in the prasugrel group, 0.91; 95% confidence interval [CI], 0.79 to 1.05; P=0.21). Similar results were observed in the overall population. The prespecified analysis of multiple recurrent ischemic events (all components of the primary end point) suggested a lower risk for prasugrel among patients under the age of 75 years (hazard ratio, 0.85; 95% CI, 0.72 to 1.00; P=0.04). Rates of severe and intracranial bleeding were similar in the two groups in all age groups. There was no significant between-group difference in the frequency of nonhemorrhagic serious adverse events, except for a higher frequency of heart failure in the clopidogrel group. CONCLUSIONS: Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed. (Funded by Eli Lilly and Daiichi Sankyo; TRILOGY ACS ClinicalTrials.gov number, NCT00699998.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to their initial events, such patients are at substantial risk for recurrent, potentially fatal events.”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [5]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citationCox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
A Prospective Natural-History Study of Coronary Atherosclerosis
Stone, G. W., Maehara, A., Lansky, A. J., Bruyne, B. D., Cristea, E., Mintz, G. S., Mehran, R., McPherson, J., Farhat, N. Z., Marso, S. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1002358 · Cited by 3,301
Authors Task Force Members, Hamm, C. W., Bassand, J., Agewall, S., Bax, J. J., Boersma, E. H., Bueno, H., Caso, P., Dudek, D., Gielen, S., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr236 · Cited by 3,096
Self-citationClopidogrel for Coronary Stenting
Gurbel, P. A., Bliden, K. P., Hiatt, B. L., & O’Connor, C. M. (2003) · Circulation · doi:10.1161/01.cir.0000072771.11429.83 · Cited by 1,544
Self-citationHamm, C. W., Bassand, J., Agewall, S., Bax, J. J., Boersma, E. H., Bueno, H., Caso, P., Dudek, D., Gielen, S., Huber, K., et al. (2012) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2011.11.006 · Cited by 1,062
Self-citationThrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Tricoci, P., Huang, Z., Held, C., Moliterno, D. J., Armstrong, P. W., de Werf, F. V., White, H. D., Aylward, P. E., Wallentin, L. C., Chen, E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109719 · Cited by 756
Self-citationWright, R. S., Anderson, J. L., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Jneid, H. M., Lincoff, A. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.02.011 · Cited by 513
Roe, M. T., Messenger, J. C., Weintraub, W. S., Cannon, C. P., Fonarow, G. C., Dai, D., Chen, A. Y., Klein, L. W., Masoudi, F. A., McKay, C. R., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.008 · Cited by 447
Self-citation
Cited by
Sorted by citations
Items 701–800 of 873
Contemporary Antiplatelet Pharmacotherapy in the Management of Acute Coronary Syndromes
Mangels, D. R., Nathan, A. S., Tuteja, S., Giri, J. S., & Kobayashi, T. (2018) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-018-0603-5 · Cited by 1
Av, A., Staferov, A. V., Konev, A. V., Afonina, N. S., Negrun, N. I., Himii, O. V., & Chelombitko, E. G. (2015) · Journal of clinical practice · doi:10.17816/clinpract6359-84 · Cited by 1
Bain, A. (2018) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2018.13.6.272 · Cited by 1
Eikelboom, J. W., & Weitz, J. I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00146-3 · Cited by 1
Prasugrel or clopidogrel for long-term secondary stroke prevention?
Hankey, G. J. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30018-3 · Cited by 1
Pinto, P., Falcão, J. L. A. A., Filho, G. A., Melo, R., Souza, R. T., Cunha, B. L., Terceiro, D. A., Mota, M., Filho, N. F., Barreto, J., et al. (2019) · Journal of Transcatheter Interventions · doi:10.31160/jotci201927a201823 · Cited by 1
Sun, M. T., Huang, S., Wiviott, S. D., Antman, E. M., Roe, M. T., Ohman, E. M., Neely, M. L., Wallentin, L. C., & Wong, C. X. J. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.01.012 · Cited by 1
Self-citationTarantini, G., Mojoli, M., Varbella, F., Caporale, R., Rigattieri, S., Andò, G., Cirillo, P. L., Pierini, S., Santarelli, A., Sganzerla, P., et al. (2020) · Trials · doi:10.1186/s13063-020-04859-1 · Cited by 1
Drugs in Myocardial Infarction
Tozzi, M., Piazza, M. D., & Meani, P. (2021) · Springer eBooks · doi:10.1007/978-3-030-71917-3_13 · Cited by 1
Eliaz, R., Mengesha, B., Ovdat, T., Iakobishvili, Z., Hasdai, D., Kheifets, M., Klempfner, R., Beigel, R., Kalmanovich, E., Alcalai, R., et al. (2021) · Cardiology · doi:10.1159/000521042 · Cited by 1
Estrategias de antiagregación plaquetaria en síndromes coronarios agudos
Costabel, J. P., Duronto, E., Nani, S., Arazi, H. C., & Guetta, J. N. (2021) · Revista Argentina de Cardiología · doi:10.7775/rac.es.v89.i2.19703 · Cited by 1
Savji, N., & Berger, J. S. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_13 · Cited by 1
Wilson, R. E., & Ziada, K. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-52993-8.00036-9 · Cited by 1
Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population
Hou, M., Hyun, K. K., Chew, D. P., Kritharides, L., Amos, D., & Brieger, D. B. (2022) · Heart Lung and Circulation · doi:10.1016/j.hlc.2022.03.007 · Cited by 1
Pharmacogenomics Informs Cardiovascular Pharmacotherapy
Babayeva, M., Azzi, B., & Loewy, Z. G. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2573-6_9 · Cited by 1
Carlin, S., & Eikelboom, J. W. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2199155 · Cited by 1
Medical Treatment of Unstable Angina and Acute Non-ST-Elevation Myocardial Infarction
Willerson, J. T., & Armstrong, P. W. (2015) · Cardiovascular medicine · doi:10.1007/978-1-4471-2828-1_18 · Cited by 1
Self-citationA Freeze on Tailored Antiplatelet Therapy?
Voora, D., & Becker, R. C. (2014) · Circulation · doi:10.1161/circulationaha.114.009930 · Cited by 1
Newer antiplatelet agents in acute coronary syndrome
Ferro, A. (2016) · BMJ · doi:10.1136/bmj.h7025 · Cited by 1
Serebruany, V. L. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht308.p2510 · Cited by 1
Vd, T., & Mehta, R. P. (1981) · PubMed · Cited by 1
Non‐ST‐Segment Elevation Acute Coronary Syndrome
Hanna, E. B. (2017) · Wiley eBooks · doi:10.1002/9781119233503.ch1 · Cited by 1
Recurrent MI and stroke post–acute coronary syndrome: Which is the lesser evil?
Lavi, S., & Džavík, V. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.02.022 · Cited by 1
Halbach, M., & Baldus, S. E. (2018) · Der Internist · doi:10.1007/s00108-018-0461-y · Cited by 1
Welsh, R. C. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz912 · Cited by 1
Unstable Angina: Presentation, Diagnosis, and Management
Manning, P., & Awtry, E. H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809657-4.99750-3 · Cited by 1
Mohiuddin, I. S. (2014) · Digital Commons @ UNT Health Science Center
Inhibitors of ADP-dependent platelet aggregation.
Knežević, A. (2014) · Cardiologia Croatica · doi:10.15836/ccar.2014.48
Antiplatelet Therapy for Patients with Acute Coronary Syndromes
Gaglia, M. A., & Matthews, R. V. (2014) · doi:10.1002/9781118493984.ch27
VerifyNow P2Y12 and Plateletworks Assays
Price, M. J., Breet, N. J., & ten Berg, J. M. (2014) · Wiley eBooks · doi:10.1002/9781118493984.ch9
Hokimoto, S., Kaikita, K., Nakaawa, K., & Ogawa, H. (2014) · Circulation
What is new in antithrombotic therapy in cardiology
Kiss, R. G. (2012) · Orvosi Hetilap · doi:10.1556/oh.2012.29505
Annala, A.-P. (2015) · UTUPub (University of Turku)
Principles of Primary and Secondary Prevention of Cardiovascular Disease
Eapen, D. J., Ghasemzadeh, N., Bellam, N., Bhatia, N. K., Valiani, K., Shen, J., VanDam, R. J., Flueckiger, P. B., Molloy, D. L., Kay, J., et al. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_53
Akutes Koronarsyndrom und antithrombozytäre Therapie
Bauer, T., & Hamm, C. W. (2014) · Herz · doi:10.1007/s00059-014-4157-3
Self-citationPlättchenhemmung und Antikoagulation beim akuten Koronarsyndrom
de Waha, S., Thiele, H., & Richardt, G. (2014) · Herz · doi:10.1007/s00059-014-4132-z
Basics of Antithrombotic Therapy for Cardiovascular Disease
Capranzano, P., & Angiolillo, D. J. (2013) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2013.06.003
Treatment With Clopidogrel After Myocardial Infarction
Lin, G., Li, Y.-H., & Han, C. (2012) · JAMA · doi:10.1001/jama.2012.28718
Hiremath, M. S., Kapoor, R., Muralidhara, B. G., Manoria, P., Lhila, S., & Kahali, D. (2013) · Indian Heart Journal · doi:10.1016/j.ihj.2013.04.025
y, P. A., Bayés‐Genís, A., de Isla, L. P., Sanchís, J. M., & Heras, M. (2012) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2012.09.002
Antiplatelet and Anticoagulant Strategies in Acute Coronary Syndrome: Where We are in 2013
Lumley, M., & Perera, D. (2013) · Future Cardiology · doi:10.2217/fca.13.21
Comparison of prasugrel and clopidogrel in the setting of ACS without revascularization
Mearns, B. M. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.133
TRIOLOGY ACS: No benefit/No harm
Elmahdy, M. F., & Antoniucci, D. (2013) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2013.18
Prise en charge non invasive des NSTE-ACS : place des inhibiteurs des récepteurs P2Y12
Schiele, F. (2013) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/s1261-694x(13)70573-x
Surgery on Patients on Antiplatelet Agents
Militello, M. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-9560-4_15
Syndrome coronaire aigu : peut-on et comment améliorer le pronostic ?
Collet, J. ‐. (2014) · Archives of Cardiovascular Diseases Supplements · doi:10.1016/s1878-6480(14)71483-1
Biondi‐Zoccai, G., Romagnoli, E., & Frati, G. (2014) · Springer eBooks · doi:10.1007/978-3-319-03746-2_42
Novel oral antiplatelets for acute coronary syndrome
Wright, P., & Antoniou, S. (2013) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2013.8.4.180
P2Y12 inhibitors in acute coronary syndromes: which and when?
Pais, P. (2013) · PubMed
Serebruany, V. L., DiNicolantonio, J. J., Can, M. M., Духанин, А. С., & Tomek, A. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.05.066
Trilogy: In search of the lost ring
Servi, S. D., & Bolognese, L. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.11.031
Acute coronary syndrome: potent oral antiplatelets
Wright, P., & Antoniou, S. (2013) · Nurse Prescribing · doi:10.12968/npre.2013.11.8.397
Strategia di gestione delle sindromi coronariche acute
Wiel, É., Assez, N., & Goldstein, P. (2014) · EMC - Urgenze · doi:10.1016/s1286-9341(14)68910-9
Dual Antiplatelet Therapy Under Scrutiny: Real Benefit and Risk Subgroups
Abreu, M. D., & Tajer, C. D. (2013) · Revista Argentina de Cardiología · doi:10.7775/ajc.81.5.2149
Lindholm, D. P. (2015) · Uppsala University Publications (Uppsala University)
Beleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
TRILOGY ACS: prasugrel of benefi t only after angiography?
Mewton, N., & Ovize, M. (2013)
Antiplatelet Therapy. New Potent P2Y12 Inhibitors
y, P. A., Morı́s, C., & Clemmensen, P. M. (2013) · Springer eBooks · doi:10.1007/978-1-4471-5424-2_2
Self-citationTherapy for Acute Coronary Syndrome and Unstable Angina
Shivapour, D. M., & Lincoff, A. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-15961-4_23
Medical Management of Coronary Artery Disease
Farag, A., & Zamvar, D. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_234
Indicaciones y duración de las combinaciones de antiagregantes
Quiles, J., & Rodríguez-Manteca, M. (2016) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2015.05.006
Save the Unlucky Unrevascularized Acute Coronary Syndrome Patient ∗
Sardella, G., & Mancone, M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.01.035
Dual antiplatelet therapy and newer agents: More efficacy but lets keep the brain safe!!
Bhatia, R., & Ola, V. (2015) · Indian Heart Journal · doi:10.1016/j.ihj.2016.01.008
Chinese Society of Cardiology of Chinese Med, Chinese Society of Cardiology of Chinese Med, Huo, Y., Ya-Ling, H., Run-Lin, G., Da-yi, H., Yun, Z., Jun-Bo, G., Yong-Qiang, Z., Xubo, S., et al. (2015) · European Heart Journal Supplements · doi:10.1093/eurheartj/suv025
Antiplatelet Agents in Diabetic Patients: Clinical Advances and Remaining Questions
Sabouret, P. F. (2014) · Journal of Clinical & Experimental Cardiology · doi:10.4172/2155-9880.1000330
Improved Outcomes in Cardiogenic Shock
Parry, N., & Spaulding, C. M. (2013) · MD Conference Express · doi:10.1177/155989771307001
Kang, H., & Roe, M. T. (2014) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9532-6
Self-citationThe role of clopidogrel in the management of ischemic heart disease
Homan, D. J., & Price, M. J. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283606957
Bibliography of One Hundred Key Papers
Jd, T., & Crea, F. (2014)
Basics of Antithrombotic Therapy for Cardiovascular Disease Targets of Platelet Inhibitors
Capranzano, P., & Angiolillo, D. J. (2013)
Role of Antiplatelet Therapy in Neurosurgery: Efficacy and Safety Profiles
Bowen, N., & Mousa, S. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-27327-3_6
Willemsen, R. T. A., Dinant, G., Verheugt, F. W. A., Cate, H. T., & Weerkamp Nico, J. (2016) · Huisarts en Wetenschap · doi:10.1007/s12445-016-0187-9
Treatment With Clopidogrel After Myocardial Infarction—Reply
Andersson, C., Gislason, G., & Torp-Pedersen, C. T. (2012) · JAMA · doi:10.1001/jama.2012.28741
Coronary thrombosis in diabetes: Are we doing enough?
Ajjan, R. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164116663795
Coronary Revascularization for Patients with Severe Coronary Artery Disease
Shiomi, H., & Kimura, T. (2015) · Journal of the Japanese Coronary Association · doi:10.7793/jcoron.21.034
Basics of Antiplatelet and Anticoagulant Therapy for Cardiovascular Disease
Capranzano, P., & Angiolillo, D. J. (2016) · Interventional Cardiology · doi:10.1002/9781118983652.ch38
PCI Strategies in Acute Coronary Syndromes without ST Segment Elevation ( NSTEACS )
Christakopoulos, G. E., Banerjee, S., & Brilakis, E. S. (2016) · Interventional Cardiology · doi:10.1002/9781118983652.ch12
Cardiac function in hypertensive patients with metabolic syndrome and microalbuminuria
Miklík, R., & Pavlušová, M. (2016) · Interní medicína pro praxi · doi:10.36290/int.2016.042
Seeking a Population That Derives a Significant Benefit from Prasugrel
Krumholz, H. M., & Sm (2012) · Journal watch · doi:10.1056/jc201208260000001
OBSOLETE: Non-ST-Elevation Myocardial Infarction: Management
Roffi, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99747-2
OBSOLETE: Unstable Angina: Presentation, Diagnosis, and Management
Awtry, E. H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99750-2
FITCHETT, D. H., Mazer, C. D., Eikelboom, J. W., & Verma, S. (2013)
An update of dual antiplatelet therapy
Ayhan, H., Karaduman, B. D., Durmaz, T., Keleş, T., & Bozkurt, E. (2017)
Kleiman, N. S. (2018) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2018.02.034
Percutaneous Coronary Interventions for NSTEMI and Unstable Angina
Noble, S., & Roffi, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-71635-0_17
Modern Antiplatelet Therapy: When Is Clopidogrel the Right Choice?
Divanji, P., & Shunk, K. (2018) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2017.0049
Antiplatelet Therapy in Cardiovascular Medicine
Savji, N., & Berger, J. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00021-2
Antiplatelet Drugs in the Management of Coronary Artery Disease
Moon, J. Y., & Angiolillo, D. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813456-6.00056-4
Dual antiplatelet therapy in coronary artery disease
Rakočević, J., Tomasevic, M. V., Aleksandric, S. B., Stojkovic, S. M., & Nedeljkovic, M. A. (2018) · Srce i krvni sudovi · doi:10.5937/siks1802045r
Classification of Platelet Aggregates by Agonist TypePreprint
Zhou, Y., Yasumoto, A., Lei, C., Huang, C., Kobayashi, H., Wu, Y., Yan, S., Sun, C., Yatomi, Y., & Goda, K. (2019) · SSRN Electronic Journal · doi:10.1101/805408
Aradi, D., Komócsi, A., Kancz, S., Nagy, G. G., Kiss, R. G., & Merkely, B. P. (2019) · Cardiologia Hungarica · doi:10.26430/chungarica.2019.49.4.267
Self-citationLa DAPT chez le patient diabétique coronarien
Dillinger, J., & Henry, P. (2019) · Archives of Cardiovascular Diseases Supplements · doi:10.1016/s1878-6480(19)30959-0
Ramakumar, V. (2019) · Journal of the Practice of Cardiovascular Sciences · doi:10.4103/jpcs.jpcs_72_19
Principaux médicaments antiagrégants : maniement, surveillance et gestion des complications
Laine, M., Frère, C., & Bonello, L. (2020)
Metadata
- Authors
- Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., Ardissino, D., Nicolau, J. C., Boden, W. E., Gurbel, P. A., Ruzyllo, W., Dalby, A. J., McGuire, D. K., Leiva-Pons, J. L., Parkhomenko, A., Gottlieb, S., Topacio, G. O., Hamm, C., Pavlides, G., Goudev, A. R., Oto, A., Tseng, C.-D., Merkely, B., Gasparovic, V., Corbalan, R., Cinteză, M., McLendon, R. C., Winters, K. J., Brown, E. B., Lokhnygina, Y., Aylward, P. E., Huber, K., Hochman, J. S., & Ohman, E. M.
- Affiliations
- Duke Medical Center (US)
- University of Alberta (CA)
- Duke University (US)
- St. Michael's Hospital (CA)
- Brigham and Women's Hospital (US)
- University of Copenhagen (DK)
- National Taiwan University (TW)
- Eli Lilly (United States) (US)
- Flinders University (AU)
- ORCID
- Roe, Matthew T.
- Armstrong, Paul W.
- Fox, Keith A.A.
- White, Harvey D.
- Prabhakaran, Dorairaj
- Goodman, Shaun G.
- Cornel, Jan H.
- Bhatt, Deepak L.
- Clemmensen, Peter
- Ardissino, Diego
- Boden, William E.
- Gurbel, Paul A.
- McGuire, Darren K.
- Leiva-Pons, Jose L.
- Parkhomenko, Alexander
- Gottlieb, Shmuel
- Hamm, Christian
- Goudev, Assen R.
- Oto, Ali
- Aylward, Philip E.
- Huber, Kurt
- Hochman, Judith S.
- Ohman, E. Magnus
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-10-04
- Volume
- 367
- Issue
- 14
- Pages
- 1297-1309
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2109577952
- Cited by
- 874
- References
- 18
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 14 · 2023: 31 · 2022: 43 · 2021: 49 · 2020: 58 · 2019: 53 · 2018: 70 · 2017: 92 · 2016: 71 · 2015: 91 · 2014: 114 · 2013: 124 · 2012: 20
- FWCI
- 71.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- Trakya University's Institutional Open Access System (Trakya University) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
- ORBi (University of Liège) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Helsinn
- Boston Scientific Corporation
- Boston VA Research Institute
- Regeneron Pharmaceuticals
- Amarin Corporation
- Medicines Company
- Regado Biosciences
- Eisai
- Astellas Pharma
- Servier
- Genentech
- Janssen Pharmaceuticals
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- prasugrel, clopidogrel, acute coronary syndrome, non-ST-elevation myocardial infarction, unstable angina, platelet aggregation inhibition, antiplatelet therapy, bleeding risk, heart failure, cardiovascular mortality, stroke, elderly patients
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Angina, Unstable, Aspirin, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Platelet Aggregation Inhibitors, Thiophenes, Ticlopidine, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
